NAV

Pipemidic acid

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Pipemidic acid is a quinolone antibiotic indicated in the treatment of susceptible urinary tract infections.

Generic Name
Pipemidic acid
DrugBank Accession Number
DB13823
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 303.3165
Monoisotopic: 303.133139435
Chemical Formula
C14H17N5O3
Synonyms
  • acido pipemidico
  • Pipemidic acid
External IDs
  • J01MB04
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofUrinary tract infection••••••••••••••••••••••••• ••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Pipemidic acid.
AceclofenacAceclofenac may increase the neuroexcitatory activities of Pipemidic acid.
AcemetacinAcemetacin may increase the neuroexcitatory activities of Pipemidic acid.
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be increased when used in combination with Pipemidic acid.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Pipemidic acid.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Pipemidic acid trihydrateN734WBH1TJ72571-82-5URMXYPLWYMOYPG-UHFFFAOYSA-N

Categories

ATC Codes
J01MB04 — Pipemidic acid
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
N-arylpiperazines
Alternative Parents
Pyrido[2,3-d]pyrimidines / Pyridinecarboxylic acids / Dialkylarylamines / Aminopyrimidines and derivatives / Vinylogous amides / Heteroaromatic compounds / Amino acids / Monocarboxylic acids and derivatives / Dialkylamines / Carboxylic acids
show 5 more
Substituents
Amine / Amino acid / Amino acid or derivatives / Aminopyrimidine / Aromatic heteropolycyclic compound / Azacycle / Carboxylic acid / Carboxylic acid derivative / Dialkylarylamine / Heteroaromatic compound
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, monocarboxylic acid, amino acid, quinolone antibiotic, pyridopyrimidine (CHEBI:75250)
Affected organisms
Not Available

Chemical Identifiers

UNII
LT12J5HVR8
CAS number
51940-44-4
InChI Key
JOHZPMXAZQZXHR-UHFFFAOYSA-N
InChI
InChI=1S/C14H17N5O3/c1-2-18-8-10(13(21)22)11(20)9-7-16-14(17-12(9)18)19-5-3-15-4-6-19/h7-8,15H,2-6H2,1H3,(H,21,22)
IUPAC Name
8-ethyl-5-oxo-2-(piperazin-1-yl)-5H,8H-pyrido[2,3-d]pyrimidine-6-carboxylic acid
SMILES
CCN1C=C(C(O)=O)C(=O)C2=CN=C(N=C12)N1CCNCC1

References

General References
  1. AIFA Product Information: Urotractin (pipemidic acid) oral capsule [Link]
Human Metabolome Database
HMDB0041989
ChemSpider
4665
RxNav
8337
ChEBI
75250
ChEMBL
CHEMBL30116
ZINC
ZINC000000057466
Wikipedia
Pipemidic_acid

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral40000000 mg
Tablet, film coatedOral
TabletOral400 mg
CapsuleOral
CapsuleOral200 MG
CapsuleOral400 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.746 mg/mLALOGPS
logP-1.5ALOGPS
logP-1.8Chemaxon
logS-2.6ALOGPS
pKa (Strongest Acidic)5.11Chemaxon
pKa (Strongest Basic)8.66Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area98.66 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity82.18 m3·mol-1Chemaxon
Polarizability30.94 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-000f-2890000000-fa2626fd59959165a510
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0009000000-f346d0fa8518f6309a43
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0uxr-0069000000-ffff1a7a9577a098fda0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0gb9-0294000000-545852783e7d4b0ad314
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014r-0592000000-b4be933137c73df3a355
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00kr-0950000000-28374d85a72be7c7b33e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01pa-1920000000-a1ae9ea00fc1f7248971
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udr-0059000000-b0997c0ca271e7b6e57e
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a59-0091000000-81ed111979767a8af752
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0090000000-843f977f6593bf6d9b6b
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0059-0090000000-0e56e14248f725d8be7e
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0563-0090000000-2a6434191ad1a11009ad
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a6r-0490000000-e763597a12c1df28a7bf
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-184.7498044
predicted
DarkChem Lite v0.1.0
[M-H]-182.4194044
predicted
DarkChem Lite v0.1.0
[M-H]-164.55296
predicted
DeepCCS 1.0 (2019)
[M+H]+185.1670044
predicted
DarkChem Lite v0.1.0
[M+H]+182.3977044
predicted
DarkChem Lite v0.1.0
[M+H]+166.91096
predicted
DeepCCS 1.0 (2019)
[M+Na]+185.2052044
predicted
DarkChem Lite v0.1.0
[M+Na]+182.8622044
predicted
DarkChem Lite v0.1.0
[M+Na]+173.60329
predicted
DeepCCS 1.0 (2019)

Enzymes

Details1. Cytochrome P450 1A2
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Gabriel L, Tod M, Goutelle S: Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers. Clin Pharmacokinet. 2016 Aug;55(8):977-90. doi: 10.1007/s40262-016-0371-x. [Article]
  2. Bertil F. Fredholm (2011). Handbook of Experimental Pharmacology, Volume 200. Springer.

Drug created at June 23, 2017 20:49 / Updated at May 21, 2021 10:23